92132-77-9

Basic information

• Product Name: Benzamide, 3-(bromoacetyl)-
• CAS NO: 92132-77-9
• Molecular Formula: C9H8BrNO2
• Molecular Weight: 242.072
• Mol File: 92132-77-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzamide, 3-(bromoacetyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, 3-(bromoacetyl)-(92132-77-9)
• EPA Substance Registry System: Benzamide, 3-(bromoacetyl)-(92132-77-9)

Safety Data

• Hazardous Substances Data: 92132-77-9(Hazardous Substances Data)

Upstream product

• 78950-32-0 3-carbamoylacetophenone 
• 92132-74-6 3-(bromoacetyl)benzenecarboximidic acid ethyl ester hydrobromide 
• 50916-55-7 3-(2-bromoacetyl)benzonitrile 
• 6136-68-1 3-acethylbenzonitrile 
• 60694-93-1 3-acetylbenzenecarboximidimic acid ethyl ester hydrochloride 

Downstream Products

• 212374-12-4 3-Oxiranyl-benzamide 
• 92132-78-0 3-[2-[(Aminoiminomethyl)Amino]-4-Thiazolyl]Benzenecarboxamide, Hydrobromide 

Relevant articles and documents

New anti-viral drugs for the treatment of the common cold

Human Rhinovirus (HRV) is the most important aetiologic agent of common cold in adults and children. HRV is a single-stranded, positive sense RNA virus and, despite the high level of conservation among different serotypes, sequence alignment of viral protease 3C with mammalian protease reveals no homology. Thus, protease 3C is an optimal target for the development of anti-HRV agents. In the present work we investigated the design, the synthesis and the development of new potential reversible inhibitors against HRV protease 3C. Docking studies on the crystallized structure of HRV2 protease 3C led us to the design and the synthesis of a series of 3,5 disubstituted benzamides able to act as analogues of the substrate. We also developed 1,3,5 trisubstituted benzamides where aromatic substitutions on the aryl ring led us to investigate the importance of π-π interaction on the stabilization of protease 3C-inhibitor complex. All structures were tested for enzymatic inhibition on HRV14 protease 3C. Results highlighted the inhibitory activity of compounds 13, 14, and 20 (91%, 81%, and 85% at 10 μM, respectively), with the latter exhibiting an ID50 (dose that inhibits 50% of the viral cytopathic effect) on HRV-14 = 25 μg/ml.

Synthesis of 3-substituted benzamides and 5-substituted isoquinolin-1(2H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP)

Inhibitors of poly(ADP-ribose)polymerase (PARP) inhibit repair of damaged DNA and thus potentiate radiotherapy and chemotherapy of cancer. 3-Substituted benzamides and 5-substituted isoquinolin-1-ones have been synthesised and evaluated for inhibition of PARP. Reduction of 3-(bromoacetyl)benzamide, followed by treatment with base, gave RS-3-oxiranylbenzamide. Reduction of 3-(hydroxyacetyl)benzonitrile with bakers' yeast gave the R-diol which was converted to R-3-(1,2-dihydroxyethyl)benzamide. Similar reduction of 3-(acetoxyacetyl)benzonitrile led towards the S-diol which was converted to its cyclic acetonide. E-2-(2,6-Dicyanophenyl)-N,N-dimethylethenamine was formed by condensation of 2,6-dicyanotoluene with dimethylformamide dimethyl acetal (DMFDMA); cyclisation under acidic conditions afforded 5-cyanoisoquinolin-1-one. Heck coupling of 5-iodoisoquinolin-1-one with propenoic acid formed E-3-(1-oxoisoquinolin-5-yl)propenoic acid. 3-Oxiranylbenzamide, 5-bromoisoquinolin-1-one and 5-iodoisoquinolin-1-one were among the most potent inhibitors of PARP activity in a preliminary screen in vitro. Copyright (C) 1998 Elsevier Science Ltd.

2-GUANYL-4-(SUBSTITUTED PHENYL) THIAZOLE DERIVATIVES

Compounds of the formula: STR1 wherein R 1 is hydrogen, cyano or cyano(lower)alkyl;R 2 is hydrogen, cyano, carboxy, carbamoyl, guanyl, (lower)alkoxyimino, hydrazinocarbonyl, (lower) alkylaminoimino, STR2 with the proviso that one but never both of R